Gary S. Goldman

Dr. Gary S. Goldman

Epidemiological Research, Physicians for Informed Consent, Costa Mesa, California, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in International Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
Gary S. GoldmanGary S. Goldman
Gary S. Goldman
Aim and background: Cytochrome P450 (CYP450) enzymes are the primary hepatic Phase I oxidative biotransformation system for many drugs and xenobiotics; variability in CYP capacity is therefore a key determinant of metabolic reserve. Reserve varies with developmental ontogeny, genotype, and acquired suppression (e.g., cytokine-mediated phenoconversion). Early infancy represents a developmental window in which clearance capacity and redox/energetic buffering may be comparatively constrained. We introduce a hypothesis-generating Three-Axis Convergence Framework (TCF) modeling interacting effects of (i) developmental/genetic reserve limits, (ii) immune-cytokine modulation of metabolism, and (iii) exposure/disposition context, and translate this synthesis into a structured postmortem interpretive tool integrated into the primary medicolegal autopsy, using an enhanced analytic panel applied selectively based on case context and specimen validity/QC to support mechanistic characterization of infant deaths remaining unexplained (often SUID/SIDS).

6 February 2002 in JAMA
Verified
Journal Article
Open access
PDF file
JSJane F. Seward
Jane F. Seward
BWBarbara M. Watson
Barbara M. Watson
CPCarol L. Peterson
Carol L. Peterson
LMLaurene Mascola
Laurene Mascola
JPJan W. Pelosi
Jan W. Pelosi
MWMelinda Wharton
Melinda Wharton
Before the introduction of varicella vaccine in 1995,1,2 varicella was a universal childhood disease in the United States.3 During the 5 years preceding implementation of the varicella vaccination program, the approximately 4 million cases that occurred every year resulted in an annual average of 11 000 hospitalizations and 100 deaths.4,5 Since varicella is not a nationally reportable disease in the United States, national varicella surveillance data through the National Notifiable Disease Surveillance System were not available to monitor the impact of the varicella vaccination program.6 Accordingly, in 1995, the Centers for Disease Control and Prevention (CDC), in collaboration with state and local health departments, instituted an active surveillance project in 3 communities. The objectives of this ongoing project were to establish baseline data and to monitor trends in varicella disease following introduction of varicella vaccine. This report summarizes trends in varicella disease and the uptake of varicella vaccine in the surveillance areas from January 1, 1995, through December 31, 2000.

1 June 2002 in Pediatrics
Verified
Journal Article
Closed access
PDF file
SHSusan Hall
Susan Hall
TMTeresa Maupin
Teresa Maupin
JSJane Seward
Jane Seward
AJAisha O. Jumaan
Aisha O. Jumaan
CPCarol Peterson
Carol Peterson
MWMelinda Wharton
Melinda Wharton
Objective. To describe the epidemiology and clinical characteristics of varicella reinfections reported to a surveillance project. Methods. We investigated varicella cases reported to a surveillance project between January 1, 1995, and December 31, 1999—with more extensive investigation of cases reporting previous varicella with onset between January 1, 1998, and September 30, 1998—to provide a more detailed description of first and second varicella infections. A simple decision tree was used to assess the likelihood that reported first and second infections were varicella. Results. Among varicella cases reported to the surveillance project, 4.5% of cases in 1995 and 13.3% of cases in 1999 reported previous varicella. More than 95% of first infections were physician diagnosed, epidemiologically linked to another case, or had a rash description consistent with varicella; the same was true for reported second infections. People who reported reinfections were generally healthy. There was a family history of repeat infections in 45% of people who reported reinfections. Conclusions. Clinical varicella reinfections may occur more commonly than previously thought. Additional studies of the predictive value of a positive varicella history and laboratory studies of reported reinfections are indicated to guide varicella vaccination policy.

1 March 2013 in Vaccine
Verified
Journal Article
Open access
Gary S. GoldmanGary S. Goldman
Gary S. Goldman
PKP.G. King
P.G. King
In a cooperative agreement starting January 1995, prior to the FDA's licensure of the varicella vaccine on March 17, the Centers for Disease Control and Prevention (CDC) funded the Los Angeles Department of Health Services' Antelope Valley Varicella Active Surveillance Project (AV-VASP). Since only varicella case reports were gathered, baseline incidence data for herpes zoster (HZ) or shingles was lacking. Varicella case reports decreased 72%, from 2834 in 1995 to 836 in 2000 at which time approximately 50% of children under 10 years of age had been vaccinated. Starting in 2000, HZ surveillance was added to the project. By 2002, notable increases in HZ incidence rates were reported among both children and adults with a prior history of natural varicella. However, CDC authorities still claimed that no increase in HZ had occurred in any US surveillance site. The basic assumptions inherent to the varicella cost-benefit analysis ignored the significance of exogenous boosting caused by those shedding wild-type VZV. Also ignored was the morbidity associated with even rare serious events following varicella vaccination as well as the morbidity from increasing cases of HZ among adults. Vaccine efficacy declined below 80% in 2001. By 2006, because 20% of vaccinees were experiencing breakthrough varicella and vaccine-induced protection was waning, the CDC recommended a booster dose for children and, in 2007, a shingles vaccination was approved for adults aged 60 years and older. In the prelicensure era, 95% of adults experienced natural chickenpox (usually as children)-these cases were usually benign and resulted in long-term immunity. Varicella vaccination is less effective than the natural immunity that existed in prevaccine communities. Universal varicella vaccination has not proven to be cost-effective as increased HZ morbidity has disproportionately offset cost savings associated with reductions in varicella disease. Universal varicella vaccination has failed to provide long-term protection from VZV disease.


20 July 2023 in Cureus
Verified
Journal Article
Open access
PDF file
NMNeil Z. Miller
Neil Z. Miller
Gary S. GoldmanGary S. Goldman
Gary S. Goldman
Introduction In 2011, using 2009 data, we published a study demonstrating that among the most highly developed nations, those requiring the most vaccine doses for their infants tended to have the least favorable infant mortality rates (r = 0.70, p < .0001). Twelve years later, we replicated our original study using 2019 data. Linear regression analysis corroborated the positive trend reported in our initial paper (r = 0.45; p < .002). Herein, we broaden our analyses to consider the effect of vaccines on neonatal and under age five mortality rates. Objective We performed several investigations to explore potential relationships between the number of early childhood vaccine doses required by nations and their neonatal, infant, and under age five mortality rates. Methods In this ecological study, we conducted linear regression analyses of neonatal, infant, and under age five vaccine doses required by nations and their neonatal, infant, and under age five mortality rates. All analyses were based on 2019 and 2021 data. We also stratified nations by the number of neonatal vaccine doses required and conducted a one-way ANOVA test and a post hoc Tukey-Kramer test to determine if there were statistically significant differences in the group mean neonatal, infant, and under age five mortality rates of nations that administered zero, one, or two neonatal vaccine doses. Results Linear regression analyses of neonatal vaccine doses required by nations in our 2021 dataset yielded statistically significant positive correlations to rates of neonatal mortality (r = 0.34, p = .017), infant mortality (r = 0.46, p = .0008), and under age five mortality (r = 0.48, p = .0004). Similar results were reported using 2019 data. Utilizing 2021 data, a post hoc Tukey-Kramer test indicated a statistically significant pairwise difference between the mean neonatal mortality rates, mean infant mortality rates, and mean under age five mortality rates of nations requiring zero vs. two neonatal vaccine doses. There was a statistically significant difference of 1.28 deaths per 1000 live births (p < .002) between the mean infant mortality rates among nations that did not give their neonates any vaccine doses and those that required two vaccine doses. Using 2019 and 2021 data, 17 of 18 analyses (12 bivariate linear regressions and six ANOVA and Tukey-Kramer tests) achieved statistical significance and corroborated the findings reported in our original study of a positive association between the number of vaccine doses required by developed nations and their infant mortality rates. Conclusions There are statistically significant positive correlations between mortality rates of developed nations and the number of early childhood vaccine doses that are routinely given. Further investigations of the hypotheses generated by this study are recommended to confirm that current vaccination schedules are achieving their intended objectives.